GGrantIndex
← Search

Pediatric Eye Disease Investigator Group Coordinating Center

$6,632,942U10FY2018EYNIH

Jaeb Center For Health Research, Inc., Tampa FL

Investigators

Linked publications, trials & patents

Paper 39620862Paper 38574967Paper 37939986Paper 37696452Paper 37440213Paper 37347490Paper 37187406Paper 36681111Paper 35914096Paper 35660415Paper 35412528Paper 35086119Paper 34793970Paper 34425237Paper 34182085Paper 33905836Paper 33705917Paper 33601046Paper 33129813Paper 32113988Paper 31862447Paper 31323203Paper 31255587Paper 30690128Paper 30615896Paper 30352226Paper 30189281Paper 29887334Paper 29196184Paper 28666772Paper 28448664Paper 28435934Paper 27812703Paper 27769584Paper 27663627Paper 27575992Paper 27506485Paper 27176554Paper 26917081Paper 26902573Paper 26072346Paper 25727586Paper 25695639Paper 25695355Paper 25676904Paper 25634146Paper 25234012Paper 24789375Paper 24568978Paper 23954210Paper 23755872Paper 23622447Paper 23563444Paper 23229693Paper 22801833Paper 22633344Paper 22459105Paper 22108357Paper 21959371Paper 21911662Paper 21907115Paper 21746992Paper 21746970Trial NCT05527015Trial NCT05462821Trial NCT03342235Trial NCT03334253Trial NCT02983552Trial NCT02807350Trial NCT02510040Trial NCT02390531Trial NCT02223650Trial NCT02200211Trial NCT01515943Trial NCT01515475Trial NCT01190813Trial NCT01032603Trial NCT01032330Trial NCT00945100Trial NCT00944710Trial NCT00789672Trial NCT00780741Trial NCT00669539Trial NCT00587171Trial NCT00525174Trial NCT00506675Trial NCT00320593Trial NCT00315328Trial NCT00315315Trial NCT00315302Trial NCT00315289Trial NCT00315198Trial NCT00310960Trial NCT00305955Trial NCT00094744Trial NCT00094692Trial NCT00094679Trial NCT00094614Trial NCT00091923Trial NCT00000170

Abstract

DESCRIPTION (provided by applicant): This application is for a 5-year extension of funding for the Pediatric Eye Disease Investigator Group (PEDIG) Coordinating Center (CC). Since its inception in 1997, PEDIG has conducted 4 protocols in strabismus, 19 protocols in amblyopia, 3 protocols in nasolacrimal duct obstruction, 2 protocols in myopia/hyperopia, & several pilot studies. By the time the funding requested in this application would begin, it is expected that 3 new protocols will have started: a randomized trial to evaluate treatment for convergence insufficiency, a randomized trial to compare botulinum toxin with incisional surgery for esotropia, and a clinical disease registry to evaluate uveitis incidence in children with juvenile idiopathic arthritis. Despite these accomplishments, many important questions and controversies remain in pediatric eye care and strabismus. PEDIG has developed, or will be developing, clinical trials to address many of these questions. These include (1) treatment strategies for children with a visual deficit despite maximal amblyopia treatment, (2) the effect of prescribing versus not prescribing spectacles for hyperopia in young children, (3) the best surgical and non-surgical treatments for intermittent exotropia, (4) risk factors for complications after cataract surgery, ad (5) the optimal treatment for convergence insufficiency. Specific aims for the next 5-year funding period for PEDIG are to: (1) complete the 7 protocols that are expected to be in progress at the time the funding period begins, (2) initiate 10 new protocols in common pediatric eye disorders where the current management does not have a proven rationale, (3) continue to expand the PEDIG network by soliciting the participation of new sites and encouraging the involvement of young investigators, (4) continue to educate pediatric ophthalmologists, pediatric optometrists, and clinical research coordinators on the principles of clinical trials and good research practices (5) train pediatric ophthalmologists and pediatric optometrists to be leaders in clinical trials an clinical research, and (6) develop new methods and outcome measures needed to conduct future amblyopia and strabismus trials as described in the parallel MCPDOC grant proposal. The Coordinating Center plays a key role in the Network's ability to achieve these goals.

View original record on NIH RePORTER →